12:00 AM
Oct 15, 2012
 |  BC Week In Review  |  Company News  |  Other News

Orexo neurology news

Orexo retained Guggenheim Securities as its financial advisor to evaluate a "full range of strategic alternatives" for its U.S. commercialization plan. Orexo expects to launch Zubsolv buprenorphine/naloxone in the U.S. in 3Q13 to treat opioid dependence. In September, Orexo submitted an NDA to FDA...

Read the full 218 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >